论文部分内容阅读
目的探讨α-2b干扰素治疗丙型病毒性肝炎(丙肝)的临床效果。方法 52例丙肝患者,均给予α-2b干扰素治疗。根据年龄不同分为24~34岁组(10例)、35~45岁组(17例)、46~54岁组(13例)及≥55岁组(12例),观察各组治疗效果;并根据病理不同将其分为急性期组(21例)、慢性期组(31例),观察治疗效果。结果年龄越大治疗效果越差,差异具有统计学意义(P<0.05);急性期组治疗总有效率为76.2%,高于慢性期组的58.1%,差异具有统计学意义(P<0.05)。结论α-2b干扰素治疗丙肝患者的临床效果显著,具有较强的抗病毒能力,对年龄较小及急性期患者的效果最佳。
Objective To investigate the clinical effect of α-2b interferon on hepatitis C virus (HCV). Methods 52 patients with hepatitis C were given interferon α-2b treatment. According to the age, the patients were divided into 24 to 34 years old group (10 cases), 35 to 45 years old group (17 cases), 46 to 54 years old group (13 cases) and 55 years old group (12 cases) The patients were divided into acute group (21 cases) and chronic phase group (31 cases) according to the pathological changes. The therapeutic effects were observed. Results The older the treatment effect was, the worse the difference was statistically significant (P <0.05). The total effective rate of acute phase group was 76.2%, which was higher than that of chronic phase group (58.1%), the difference was statistically significant (P <0.05) . Conclusion The clinical efficacy of interferon alfa-2b in the treatment of hepatitis C patients is significant, with strong anti-virus ability and the best effect in patients with younger and acute phase.